Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2014 by Massachusetts General Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Carolyn N. Krasner, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01652079
First received: July 25, 2012
Last updated: January 22, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)